Eidos Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Business Update
Eidos Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Business Update
February 26, 2020 at 4:30 PM EST
“2019 marked another year of significant scientific, clinical, and corporate progress at Eidos. We presented positive data from the ongoing phase 2 open label extension study suggesting long-term tolerability of AG10 and stabilization of transthyretin amyloid cardiomyopathy disease measures,” said
2019 Highlights
- Presented interim analysis of the ongoing Phase 2 open label extension study of AG10 in patients with TTR amyloid cardiomyopathy at the AHA 2019 Scientific Sessions in a Late-Breaking Featured Science Oral Presentation. Rates of mortality and cardiovascular hospitalization observed in exploratory analysis were lower than rates observed in placebo-treated participants in the ATTR-ACT study. Serum TTR levels, a prognostic indicator of survival, were elevated and maintained in the normal range throughout the study duration.
- Initiated and continued enrollment of Phase 3 study of AG10 in ATTR-CM (ATTRibute-CM).
- Published Phase 2 data of AG10 in ATTR-CM in the
Journal of the American College of Cardiology (JACC). - Presented sub-group analysis of Phase 2 data in ATTR-CM at
American College of Cardiology (ACC) Scientific Sessions . - Published Phase 1 data of AG10 in healthy volunteers in Clinical Pharmacology in Drug Development.
- Granted Alexion Pharmaceuticals, Inc. an exclusive license to develop and commercialize AG10 in
Japan for an upfront payment of$25.0 million and an equity investment of$25.0 million . - Appointed
Uma Sinha , Chief Scientific Officer, to the Board of Directors. - Plan to initiate Phase 3 study of AG10 in ATTR-PN (ATTRibute-PN) in the first half of 2020.
Fourth Quarter and Full-Year 2019 Financial and Operating Results
Cash and cash equivalents totaled
Eidos reported a net loss attributable to common stockholders of approximately $37.8 million or
Research and development expenses for the full year 2019 were $46.9 million, as compared to $28.5 million for the prior year. Research and development expenses for the fourth quarter of 2019 were $13.9 million, as compared to $8.3 million for the same period in the prior year. Research and development expenses for the fourth quarter included costs related to contract manufacturing and the preparation for and conduct of clinical trials of AG10.
General and administrative expenses for the full year 2019 were $17.8 million, as compared to $9.2 million for the prior year. General and administrative expenses for the fourth quarter of 2019 were $5.5 million, as compared to $2.4 million for the same period in the prior year. The increase in general and administrative expense in these periods was due primarily to an increase in professional service fees, salaries and employee-related expense primarily due to an increase in headcount to support the growth of our operations, and other administrative expenses.
About AG10
AG10 is an investigational, orally-administered small molecule designed to potently stabilize tetrameric transthyretin, or TTR, thereby halting at its outset the series of molecular events that give rise to TTR amyloidosis, or ATTR. In a randomized, placebo-controlled Phase 2 clinical trial in patients with symptomatic ATTR-CM, AG10 was generally well tolerated, demonstrated greater than 90% average TTR stabilization at day 28, and increased serum TTR concentrations, a prognostic indicator of survival in a retrospective study of ATTR-CM patients, in a dose-dependent manner. The open label extension of this Phase 2 clinical trial, or the Phase 2 OLE, identified no safety signals of potential clinical concern associated with administration of AG10 15 months after study initiation. In an exploratory analysis, lower rates of all-cause mortality (including death and cardiac transplantation) and cardiovascular hospitalizations were observed in study participants than in placebo-treated ATTR-CM patients in the ATTR-ACT study. Cardiac biomarkers and echocardiographic parameters were stable in the AG10 Phase 2 OLE.
AG10 is currently being studied in a Phase 3 clinical trial in patients with ATTR-CM (ATTRibute-CM), and we expect to initiate a Phase 3 clinical trial of AG10 in patients with ATTR-PN in the first half of 2020.
AG10 was designed to mimic a naturally-occurring variant of the TTR gene (T119M) that is considered a rescue mutation because co-inheritance has been shown to prevent ATTR in individuals also inheriting a pathogenic, or disease-causing, mutation in the TTR gene. To our knowledge, AG10 is the only TTR stabilizer in development that has been observed to mimic the stabilizing structure of this rescue mutation.
About transthyretin amyloidosis (ATTR)
There is significant medical need in ATTR given the large patient population and limited current standard of care. ATTR is caused by the destabilization of TTR due to inherited mutations or aging and is commonly divided into three distinct categories: wild-type ATTR cardiomyopathy (ATTRwt-CM), mutant ATTR cardiomyopathy (ATTRm-CM), and ATTR polyneuropathy (ATTR-PN). The worldwide prevalence of each disease is approximately 400,000 patients, 40,000 patients and 10,000 patients, respectively.
All three forms of ATTR are progressive and fatal. For patients with ATTRwt-CM and ATTRm-CM, symptoms usually manifest later in life (age 50+), with median survival of three to five years from diagnosis. ATTR-PN either presents in a patient's early 30s or later (age 50+), and results in a median life expectancy of five to ten years from diagnosis for untreated patients. Progression of all forms of ATTR causes significant morbidity, impacts productivity and quality of life, and creates a significant economic burden due to the costs associated with progressively greater patient needs for supportive care.
About
Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act. All statements other than statements of historical facts, including the statements about the potential therapeutic and clinical benefits of AG10, our ability to enroll patients in and conduct the ATTRibute-CM trial and to initiate and conduct our planned Phase 3 clinical trial of AG10 in ATTR-PN in accordance with our plans, future clinical and regulatory milestones of AG10, the timing of these events, the indications we intend to pursue and our possible clinical or other business strategies, and our ability to fund our clinical development plans, are forward-looking statements. Forward-looking statements can be identified by terms such as “believes,” “expects,” “plans,” “potential,” “would” or similar expressions and the negative of those terms. These forward-looking statements are based on our management’s current beliefs and assumptions about future events and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, risks and uncertainties related to: our limited operating history and historical losses, our liquidity to fund the development of AG10 through current and future milestones, our ability to raise additional funding to complete the development of AG10, our dependence on the success of AG10, our ability to enroll patients in our ongoing and planned clinical trials, results from our clinical trials and pre-clinical studies and those of third parties working in the same area as our product candidate, our ability to advance AG10 in clinical development in accordance with our plans, and our dependence on third parties in connection with our manufacturing, clinical trials and pre-clinical studies. Additional risks and uncertainties that could affect our future results are included in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended
Condensed Statements of Operations
(Unaudited)
(In thousands, except share and per share data)
| Three Months Ended | Year Ended | ||||||||||||||
| 2019 | 2018 | 2019 | 2018 | ||||||||||||
| License revenue | $ | - | $ | - | $ | 26,691 | $ | - | |||||||
| Operating expenses*: | |||||||||||||||
| Cost of license revenue | - | - | 2,500 | - | |||||||||||
| Research and development | 13,858 | 8,323 | 46,891 | 28,539 | |||||||||||
| General and administrative | 5,466 | 2,382 | 17,751 | 9,240 | |||||||||||
| Total operating expenses | 19,324 | 10,705 | 67,142 | 37,779 | |||||||||||
| Loss from operations | (19,324 | ) | (10,705 | ) | (40,451 | ) | (37,779 | ) | |||||||
| Interest expense | (327 | ) | - | (327 | ) | (1,011 | ) | ||||||||
| Other income (expense), net | 671 | 851 | 2,943 | (1,935 | ) | ||||||||||
| Net and comprehensive loss | (18,980 | ) | (9,854 | ) | (37,835 | ) | (40,725 | ) | |||||||
| Deemed dividend related to redemption feature embedded in Convertible Promissory Notes payable to stockholders | - | - | - | (6,523 | ) | ||||||||||
| Gain on extinguishment of Convertible Promissory Notes payable to stockholders | - | - | - | 7,436 | |||||||||||
| Net loss attributable to common stockholders | $ | (18,980 | ) | $ | (9,854 | ) | $ | (37,835 | ) | $ | (39,812 | ) | |||
| Net loss per share attributable to common stockholders | $ | (0.51 | ) | $ | (0.27 | ) | $ | (1.03 | ) | $ | (1.86 | ) | |||
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 37,277,751 | 36,128,132 | 36,624,692 | 21,366,995 | |||||||||||
| * Includes stock-based compensation as follows | |||||||||||||||
| Research and development | $ | 683 | $ | 456 | $ | 2,313 | $ | 1,325 | |||||||
| General and administrative | 965 | 372 | 3,060 | 1,201 | |||||||||||
| Total stock-based compensation expense | $ | 1,648 | $ | 828 | $ | 5,373 | $ | 2,526 | |||||||
Condensed Balance Sheets
(Unaudited)
(In thousands)
| 2019 | 2018 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash | $ | 191,157 | $ | 157,147 | |||
| Related party receivable | 85 | 34 | |||||
| Prepaid expenses and other current assets | 4,678 | 1,789 | |||||
| Total current assets | 195,920 | 158,970 | |||||
| Property and equipment, net | 1,259 | 209 | |||||
| Operating lease, right of use asset | 4,010 | - | |||||
| Other assets | 2,631 | 933 | |||||
| Total assets | $ | 203,820 | $ | 160,112 | |||
| Liabilities and Stockholders’ Equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 3,151 | $ | 1,956 | |||
| Related party payable | 316 | 256 | |||||
| Lease liabilities | 554 | ||||||
| Accrued expenses and other current liabilities | 6,409 | 2,577 | |||||
| Total current liabilities | 10,430 | 4,789 | |||||
| Debt, non-current | 16,112 | - | |||||
| Lease liabilities, non-current | 4,591 | - | |||||
| Embedded Derivative | 1,165 | - | |||||
| Other liabilities | 95 | 316 | |||||
| Total liabilities | 32,393 | 5,105 | |||||
| Stockholders’ equity (deficit): | |||||||
| Common stock | 38 | 37 | |||||
| Additional paid-in capital | 274,494 | 220,240 | |||||
| Accumulated deficit | (103,105 | ) | (65,270 | ) | |||
| Total stockholders’ equity | 171,427 | 155,007 | |||||
| Total liabilities and stockholders’ equity | $ | 203,820 | $ | 160,112 | |||
Media Contact:
For Investors
Source: Eidos Therapeutics, Inc.